Cytotoxic and Antileishmanial Potential of Pilocarpus microphyllus Essential Oil: In Vitro and In Silico Study
- PMID: 41532848
- PMCID: PMC12802534
- DOI: 10.1002/cbdv.202502175
Cytotoxic and Antileishmanial Potential of Pilocarpus microphyllus Essential Oil: In Vitro and In Silico Study
Abstract
The essential oil of Pilocarpus microphyllus (jaborandi) (EOJ), a species traditionally recognized for its alkaloid-based pharmacological properties, remains poorly investigated despite its richness in bioactive terpenes. In this study, the chemical profile of EOJ obtained from fresh and dried leaves was determined by gas chromatography-mass spectrometry, revealing 24 constituents, predominantly γ-cadinene (23.6%) and trans-caryophyllene (22.9%). Antifungal activity was observed against Cryptococcus neoformans (minimum inhibitory concentration: 149-2395 µg/mL), while antileishmanial potential was confirmed against Leishmania amazonensis promastigotes (half-maximal inhibitory concentration [IC50]: 22.8-25.2 µg/mL). EOJ also exhibited cytotoxic effects on HCT-116 and PC-3 cell lines (IC50: 27.8-29.2 µg/mL). In silico studies revealed strong binding affinities with therapeutic targets: γ-cadinene to Nectin-4 (ΔG = -7.3 kcal/mol) and trans-caryophyllene to lanosterol 14α-demethylase (ΔG = -5.7 kcal/mol). Absorption, distribution, metabolism, excretion, and toxicity predictions indicated favorable oral absorption and low genotoxicity. Altogether, EOJ demonstrates multitarget bioactivity, and its major constituents represent promising leads for antifungal, antileishmanial, and anticancer drug development.
Keywords: Pilocarpus microphyllus; cytotoxicity; molecular docking; trans‐caryophyllene; γ‐cadinene.
© 2026 The Author(s). Chemistry & Biodiversity published by Wiley‐VHCA AG.
Conflict of interest statement
The authors declare no conflicts of interest.
Figures
References
-
- Singh P., Garasiya T., Ajila V., Sengupta S., Datta A., and Nivean M., “Efficacy and Safety of Pilocarpine Hydrochloride Ophthalmic Solution USP 1.25% w/v Versus Placebo Ophthalmic Solution for the Treatment of Presbyopia—A Multicentric Clinical Trial,” Indian Journal of Ophthalmology 73 (2025): 1251, 10.4103/ijo.IJO_1172_24. - DOI - PMC - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
